Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.89
-0.13 (-1.39%)
Mar 21, 2025, 10:19 AM EDT - Market open
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Amneal Pharmaceuticals stock have an average target of 10.8, with a low estimate of 8.00 and a high estimate of 12. The average target predicts an increase of 21.55% from the current stock price of 8.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +23.80% | Mar 3, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $9 → $12 | Hold → Buy | Upgrades | $9 → $12 | +35.06% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | +23.80% | Nov 11, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +35.06% | Oct 2, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $9 | Sell → Hold | Upgrades | $9 | +1.29% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
3.07B
from 2.79B
Increased by 9.77%
Revenue Next Year
3.22B
from 3.07B
Increased by 4.99%
EPS This Year
0.72
from -0.38
EPS Next Year
0.81
from 0.72
Increased by 12.18%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.2B | 3.5B | 3.8B |
| Avg | 3.1B | 3.2B | 3.4B |
| Low | 2.8B | 3.0B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 16.3% | 13.1% | 18.1% |
| Avg | 9.8% | 5.0% | 4.8% |
| Low | 0.3% | -3.8% | -6.1% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 0.85 | 0.86 |
| Avg | 0.72 | 0.81 |
| Low | 0.57 | 0.75 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | 19.9% |
| Avg | - | 12.2% |
| Low | - | 5.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.